^
Association details:
Biomarker:No biomarker
Cancer:Chronic Lymphocytic Leukemia
Drug:Rixathon (rituximab biosimilar) (CD20 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
06/15/2017
Excerpt:
Rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia.
Secondary therapy:
Chemotherapy